We are leaders in
Oncolytic Immunotherapies
ImmVirX is a clinical stage oncology company developing receptor targeted oncolytic RNA immunotherapies to enable powerful and durable responses in the most globally prevalent cancers with high unmet need.
What we are up to
ImmVirX is actively progressing its novel immunotherapies in the clinic, targeting some of the most prevalent cancer types where patients have limited treatment options.
Our novel oncolytic immunotherapies harness the power of viruses to preferentially infect and kill cancer cells and induce systemic anti-tumour immune responses.
The proprietary bio-selected RNA viruses target specific receptor proteins highly expressed on a range of cancer cell types, allowing them to selectively enter, replicate in, and destroy tumour cells while creating beneficial changes in the tumour micro-environment, potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.
In this way, our oncolytic immunotherapies are intended to increase the effectiveness of current therapies, primarily immune checkpoint inhibitors and CAR-T cells, in fighting cancers of high unmet need including colorectal, gastric, hepatocellular and ovarian cancer.
View our Corporate Investor Deck
In the News
Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.
